<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2853">
  <stage>Registered</stage>
  <submitdate>28/07/2010</submitdate>
  <approvaldate>28/07/2010</approvaldate>
  <nctid>NCT01172366</nctid>
  <trial_identification>
    <studytitle>A Study to Evaluate the Potential for Interpersonal Transfer of Testosterone Following Single Dose Application</studytitle>
    <scientifictitle>A Phase I Study to Evaluate the Potential for Interpersonal Transfer of Testosterone Following Single Dose Application of 2% Testosterone Metered Dose (MD) Lotion®</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>MTE12</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypogonadism</healthcondition>
  </conditions>
  <interventions>
    <interventions />
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pharmacokinetics - Single dose pharmacokinetic parameters (AUC0-24, AUC0-72, Cmin, Cmax, and tmax) are to be reported for total testosterone, free testosterone and DHT.</outcome>
      <timepoint>72 hours total</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy Male Subjects:

        Inclusion:

          -  Healthy male subjects aged = 18 and = 45, who have no history of clinically
             significant medical disorders and who have passed the required laboratory and physical
             screening tests.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Exclusion:

          -  Men with a history of allergy/sensitivity to testosterone or in whom testosterone
             therapy is contraindicated, or a clinically significant finding on physical exam or
             skin disorder.

        Healthy Female Subjects:

        Inclusion:

          -  Healthy premenopausal women aged = 18 and = 45, who have no history of clinically
             significant medical disorders and who have passed the required laboratory and physical
             screening tests.

        Exclusion:

          -  Women with a history of allergy/sensitivity to testosterone or in whom testosterone
             therapy is contraindicated, or a clinically significant finding on physical exam or
             skin disorder.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>QPharm - Brisbane</hospital>
    <postcode> - Brisbane</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Acrux DDS Pty Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The hypotheses for this study is that there is no transfer of testosterone from male (donor)
      subjects to female (recipient) subjects when contact is made 2 hours post application of 2%
      Testosterone MD-Lotion® if the donor has a covered application area with a T-shirt.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01172366</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Tina Soulis, BSc, PhD</name>
      <address>Acrux DDS Pty Ltd</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>